A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.
Advanced Solid Tumor
DRUG: QLS12004
AEs, TEAEs, TRAEs, SAEs, Incidence, severity and relevance to the trial drug of adverse events (AEs), treatment-related adverse events (TEAEs), treatment-related adverse events (TRAEs) and serious adverse events (SAEs), up to 2 years|DLT, Dose-limiting toxicity, Up to 21 days after the first dose|MTD, maximum tolerated dose, Up to 21 days after the first dose|RP2D, recommended phase II dose, Up to 21 days after the first dose
Tmax, Time to Reach Maximum (peak) Plasma Concentration Following Drug Administration, up to 2 years|Cmax, Maximum Plasma Drug Concentration, up to 2 years|ORR, Objective Response Rate, up to 2 years|DCR, Disease Control Rate, up to 2 years|PFS, Progression-free Survival, up to 2 years|OS, Objective Response Rate, up to 2 years
This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.The frequency of administration and the dose to be administered in subsequent clinical studies will be determined based on a combination of preliminary data.